Results 151 to 160 of about 116,210 (265)

Clinical and immunological effects of adding cyclophosphamide to pomalidomide–dexamethasone in relapsed‐refractory multiple myeloma: The randomized MUKseven trial

British Journal of Haematology, EarlyView.
Summary There is an ongoing need for accessible combination therapies for patients with relapsed‐refractory multiple myeloma (RRMM), alongside a growing interest in understanding their immunological effects, particularly on T‐cell populations. Myeloma UK (MUK) MUKseven (NCT02406222) was an academic, UK multicentre randomized controlled, open‐label ...
Andrew Hall, James Croft, Katrina Walker, Kevin Boyd, Sadie Roberts, Amy Holroyd, Mamta Garg, Elsa Ferris, Gordon Cook, William E. Pierceall, Anjan Thakurta, Anita Gandhi, Charlotte Pawlyn, Sarah R. Brown, Martin Kaiser   +14 more
wiley   +1 more source

Sacituzumab-induced severe or febrile neutropenia and G-CSF utilization and cost for advanced HER2-negative breast cancer: a single-center retrospective analysis. [PDF]

Breast Cancer Res Treat
Tam G, Waddell D, Freeman JQ, Chen N, Yang H.   +4 more
europepmc   +1 more source

Drug Neutropenia [PDF]

BMJ, 1970
openaire   +2 more sources

The impact of NK1 receptor antagonist selection on chemotherapy-related adverse events: a retrospective study of adverse events in paclitaxel or nab-paclitaxel and carboplatin combination therapy with fosnetupitant and aprepitant use. [PDF]

Front Pharmacol
Yamaoka K, Kajita S, Kume M, Hirabatake M, Sato Y, Hashida T, Tachikawa R, Muroi N.   +7 more
europepmc   +1 more source

[Febrile neutropenia].

Ryoikibetsu shokogun shirizu, 2001
openaire   +2 more sources

Chronic Neutropenia [PDF]

Archives of Disease in Childhood, 1957
openaire   +2 more sources

Hydroxyurea (hydroxycarbamide) use in adults with haemoglobin SC disease: A real‐world study in Quebec

British Journal of Haematology, EarlyView.
Summary Haemoglobin SC (HbSC) disease is the second most prevalent form of sickle cell disease, but evidence for hydroxyurea (hydroxycarbamide; HU) to prevent pain episodes was limited until the prospective identification of variables as outcomes for treatment (PIVOT) trial.
Alice Girard, Laurianne Charette, Mélissa Haouchine, Laurence Bozec, Mohamed Zakaria Bachir Bouyadjera, Mariane Poitras, Vincent‐Thierry Taillefer, Chloé Trudeau, Yves Pastore, Nathalie Letarte, Stéphanie Forté   +10 more
wiley   +1 more source

Hepatic Candidiasis Following Drug-Induced Neutropenia in ANCA-Associated Vasculitis: A Diagnostic Challenge. [PDF]

ACG Case Rep J
Park JH, Kumar R, Vikash F, Kumar S, Nankani A, Kajal D, Radulovic M, Patel S.   +7 more
europepmc   +1 more source

Drug-induced neutropenia: A comprehensive pharmacovigilance study of the FAERS database. [PDF]

Medicine (Baltimore)
Li J, Wang Y, Gao L, Jia J, Liu J, Jiang Z.   +5 more
europepmc   +1 more source

Comparative effectiveness of chimeric antigen receptor (CAR) T‐cell therapy versus historical controls in patients with relapse/refractory aggressive B‐cell lymphoma: An indirect treatment comparison in the real‐world setting

British Journal of Haematology, EarlyView.
Summary Single‐arm studies demonstrate dramatic improvements in survival in patients with relapsed/refractory (R/R) aggressive B‐cell lymphomas but with significant toxicities and at exceptionally high costs. The objective of this study was to evaluate the real‐world health outcomes of aggressive B‐cell lymphoma patients treated with publicly funded ...
Pierre J. A. Villeneuve, Lee Mozessohn, Nibene H. Somé, Rebecca E. Mercer, Lisa Masucci, Tom Kouroukis, Chris Bredeson, Suriya Aktar, Qi Guan, Anca Prica, Christine I. Chen, Danielle Rodin, Matthew Cheung, Munaza Chaudhry, Scott Gavura, Cassandra McKay, William W. L. Wong, Kelvin K. W. Chan   +17 more
wiley   +1 more source